Some people may require higher doses. Your doctor will adjust the dose of this medication as needed. Rabeprazole delayed release tablet has been designed to work throughout the day, and therefore needs to be taken only once daily. This medication may be taken with or without food. Swallow the tablets whole with a beverage.
Do not chew, crush, or split the tablets. Most people will experience some improvements in symptoms 1 to 2 weeks after starting rabeprazole. It may take up to 4 weeks for people to experience maximum benefit from this medication. Keep taking this medication and finish all the tablets as recommended by your doctor even if you start to feel better. If the symptoms that were causing you problems have not gone away by the time you finish your medication or as discussed with your doctor, call your doctor.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor. It is important to take this medication exactly as prescribed by your doctor.
If you miss a dose, take it as soon as possible and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.
Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store this medication at room temperature, protect it from light and moisture, and keep it out of the reach of children. Do not dispose of medications in wastewater e. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Who should NOT take this medication? Do not take this medication if you: Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent. Gastrin values returned to pre-treatment levels, usually within 1 to 2 weeks after discontinuation of therapy. Human gastric biopsy specimens from the antrum and the fundus from over patients receiving rabeprazole or comparator treatment for up to 8 weeks have not detected changes in ECL cell histology, degree of gastritis, incidence of atrophic gastritis, intestinal metaplasia or distribution of H.
In over patients followed for 36 months of continuous therapy, no significant change in findings present at baseline was observed. Systemic effects of rabeprazole sodium in the CNS, cardiovascular and respiratory systems have not been found to date. Rabeprazole sodium, given in oral doses of 20 mg for 2 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, oestrogen, testosterone, prolactin, cholecystokinin, secretin, glucagon, follicle stimulating hormone FSH , luteinising hormone LH , renin, aldosterone or somatotrophic hormone.
Clinical efficacy and safety Studies in healthy subjects have shown that rabeprazole sodium does not have clinically significant interactions with amoxicillin. Rabeprazole does not adversely influence plasma concentrations of amoxicillin or clarithromycin when co-administered for the purpose of eradicating upper gastrointestinal H. Rabeprazole sodium is an enteric-coated gastro-resistant tablet formulation of rabeprazole sodium. This presentation is necessary because rabeprazole is acid-labile.
Absorption of rabeprazole therefore begins only after the tablet leaves the stomach. Absorption is rapid, with peak plasma levels of rabeprazole occurring approximately 3. Peak plasma concentrations Cmax of rabeprazole and AUC are linear over the dose range of 10 mg to 40 mg. Additionally the bioavailability does not appear to increase with repeat administration. In healthy subjects the plasma half-life is approximately one hour range 0. There was no clinically relevant interaction with food.
Neither food nor the time of day of administration of the treatment affect the absorption of rabeprazole sodium. Rabeprazole sodium, as is the case with other members of the proton pump inhibitor PPI class of compounds, is metabolised through the cytochrome P CYP hepatic drug metabolising system. In these studies, at expected human plasma concentrations rabeprazole neither induces nor inhibits CYP3A4; and although in vitro studies may not always be predictive of in vivo status these findings indicate that no interaction is expected between rabeprazole and cyclosporin.
In humans the thioether M1 and carboxylic acid M6 are the main plasma metabolites with the sulphone M2 , desmethyl-thioether M4 and mercapturic acid conjugate M5 minor metabolites observed at lower levels. Only the desmethyl metabolite M3 has a small amount of anti-secretory activity, but it is not present in plasma. Following a single 20 mg 14C labelled oral dose of rabeprazole sodium, no unchanged drug was excreted in the urine.
The remainder of the dose was recovered in faeces. Adjusted for body mass and height, there are no significant gender differences in pharmacokinetic parameters following a single 20 mg dose of rabeprazole. The mean half-life of rabeprazole was 0. The clearance of the drug in patients with renal disease requiring maintenance haemodialysis was approximately twice that in healthy volunteers.
Following a single 20 mg dose of rabeprazole to patients with chronic mild to moderate hepatic impairment the AUC doubled and there was a fold increase in half-life of rabeprazole compared to the healthy volunteers.
However, following a 20 mg dose daily for 7 days the AUC had increased to only 1.
© Copyright 2017 Rabeprazole Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD.